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John F. DiPersioPatients undergoing peripheral blood stem cell
mobilization for autologous transplantation may fail
to achieve the generally accepted minimum threshold
for transplantation ($2  106 CD34/kg) despite using
optimal doses of granulocyte-colony stimiulating
factor (G-CSF) or chemotherapy plus G-CSF. Failure
rates vary from center to center but are felt to be
highest in certain diseases such as non-Hodgkin’s
lymphoma (NHL), Hodgkin’s disease (HD), and in
heavily pretreated patients with multiple myeloma
(MM). Although there is both vigorous debate and
varying understanding of the optimal methods for
mobilization (G-CSF alone versus chemotherapy
plus G-CSF) there is general agreement that these dis-
eases and various risk factors are associated with high
rates of stem cell collection failure. The known risk
factors include age, high-risk diseases such as lym-
phoma, progressive disease, bone marrow involve-
ment, previous radiation therapy, premobilization
platelet counts, exposure to repetitive cycles of chemo-
therapy with specific chemotherapies such as fludara-
bine and biologic therapies such as lenalidomide
(.3-6 cycles). There are likely other risk factors that
are either poorly understood (SDF-1 and CXCR4 sin-
gle nucleotide polymorphisms, sympathetic nervous
system function, and innervation of the bone marrow)
or not yet identified (diabetes, germ line polymor-
phisms in genes that control stem cell quiescence and
mass) [1,2]. Because the SDF-1/CXCR4 axis is critical
for stem cell trafficking and homing any agent that
modulates this axis or interrupts this ligand-receptor
interaction would be expected to promote stem cell
trafficking from the bone marrow to the peripheral
blood yielding enhanced stem cell collections.ivision ofOncology, SitemanCancer Center,Washington
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6/j.bbmt.2011.12.578The largest retrospective analysis of patients un-
dergoing stem cell mobilization for NHL, HD, and
MM demonstrated that magnitude of mobilization
failure is greatest in NHL (25%) and lowest in
MM (8%) [3]. These data have now been confirmed
and validated by many groups. Pusic et al. [3] also
found that although chemotherapy plus G-CSFmobi-
lized higher median CD34/kg than G-CSF alone the
failure rates of achieving a minimum threshold of
$2  106 CD34/kg after a maximum of 5 20-liter
apheresis procedures were identical in each disease
group (NHL, HD, and MM) whether the patients
were mobilized with G-CSF plus chemotherapy or
G-CSF alone. Furthermore, a subset analysis of over
280 patients who required remobilization demon-
strated that a second mobilization attempt was suc-
cessful only 25% of the time regardless of the use
of G-CSF, granulocyte macrophage-colony stimulat-
ing factor plus G-CSF or chemotherapy plus G-CSF
as an alternative remobilization strategy while remo-
bilization with G-CSF plus plerixafor resulted
in successful remobilization in approximately 60% of
patients.
The report of Attolica et al. [4] reported similar
results in a small cohort of patients (n 5 37) with
NHL and MM who failed initial mobilization (or
were considered high risk for mobilization failure)
with either G-CSF or G-CSF plus chemotherapy.
The authors found, similar to other groups, that
the addition of plerixafor to chemotherapy plus
G-CSF was well tolerated and dramatically reduced
mobilization failure rates, similar to those reported
by Pusic et al, from 75% to 27%. Although their
study could not compare the failure rates of second
mobilization with G-CSF plus chemotherapy plus
plerixafor to G-CSF plus perixafor other reports
suggest that the 2 approaches are similar and point
to the key role of adding plerixafor to either
backbone in NHL and MM patients who fail initial
mobilization [5,6]. Therefore, this study represents
one of many that have demonstrated that the addi-
tion of plerixafor will increase the CD34/mL by 2-
to 4-fold (in 4-12 hours) and will reduce the failure
of second mobilization by 2- to 3-fold. In fact, the
largest retrospective study of remobilization in
MM, HD, and NHL patients who failed initial mo-
bilization performed by the European Consortium
of Stem Cell Mobilisation (n 5 580) revealed almost159
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plerixafor with either G-CSF or chemotherapy
plus G-CSF successfully achieving the threshold of
$2  106 CD34/kg. This report recapitulated the
results of Attolica et al. [4] demonstrating that the
yields of CD34/kg after remobilization with plerix-
afor are the best in MM patients (88% success), the
worst in NHL patients (63% success) and, most
importantly, that G-CSF plus plerixafor was at least
as effective at remobilization as G-CSF plus chemo-
therapy plus plerixafor [6].
The report of Attolica et al. [4] confirm and val-
idate the results of many other groups suggesting
that the addition of a small molecule competitive in-
hibitor of CXCR4, plerixafor, provides new hope for
those unfortunate patients with limited marrow re-
serves and who fail initial mobilization and provides
a pathway to autologous stem cell transplantation as
potentially curative therapy for patients with hema-
tologic malignancies. Although this and other re-
ports are consistent and compelling, prospective
randomized trials will be needed to definitively
confirm the role of plerixafor to enhance the mobi-
lization of peripheral blood stem cells in patients
who are undergoing mobilization or remobilization
with a backbone of chemotherapy plus G-CSF.From the Leukemia Program, Department of Hematologic
Oncology and Blood Disorders, Cleveland Clinic Taussig
Cancer Institute, Cleveland, Ohio.
Editorial onArmand et al., ‘‘ClassifyingCytogenetics in Patientswith
Acute Myelogenous Leukemia in Complete Remission Under-
going Allogeneic Transplantation: A Center for International
Blood and Marrow Transplant Research Study.’’ BBMT 2011.
Correspondence and reprint requests: Mikkael A. Sekeres, MD,MS,
Director, Leukemia Program, Associate Professor of Medicine,
Department of Hematologic Oncology and Blood Disorders,
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
44195 (e-mail: sekerem@ccf.org).
Received November 22, 2011; accepted November 23, 2011
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2011.11.022ACKNOWLEDGMENTS
Financial disclosure: Dr. DiPersio has received hon-
oriaria from Genzyme.REFERENCES
1. Schroeder MA, DiPersio JF. Mobilization of hematopoietic stem
and leukemia cells. J Leuk Biol. 2012;91:1-11.
2. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal
and hematopoietic stem cells form a unique bone marrow niche.
Nature. 2010;466:829-836.
3. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and re-
mobilization strategies on achieving sufficient stem cell yields for
autologous transplantation. Biol Blood Marrow Transplant. 2008;
14:1045-1056.
4. Attolica I, PavoneV,Ostuni A, et al. Plerixafor added to chemother-
apy plusG-CSF is safe and allows adequate PBSC collection in pre-
dictedpoormobilizerpatientswithmultiplemyelomaor lymphoma.
Biol Blood Marrow Transplant. 2011;18:241-249.
5. Calandra G,McCarty J, McGuirk J, et al. AMD3100 plus G-CSF
can successfully mobilize CD341 cells from non-Hodgkin’s lym-
phoma, Hodgkin’s disease and multiple myeloma patients previ-
ously failing mobilization with chemotherapy and/or cytokine
treatment: compassionate use data. Bone Marrow Transplant.
2008;41:331-338.
6. Kubel K, Fresen M, Apperley J, et al. European data on stem cell
mobilizationwith plerixafor in non-Hodgkin’s lymphoma,Hodg-
kin’s lymphoma, and multiple myeloma patients. A subgroup
analysis of the European Consortium of stem cell mobilization.
Bone Marrow Transplant. 2011 Nov 14 [Epub ahead of print].My AML Cytogenetics Classification Scheme
Is Better Than Yours
Mikkael A. SekeresGrowing up in Rhode Island, my brother and I
spent hours – I mean, hours – in the schoolyard around
the block from our house arguing over which baseball
team was better: the Yankees or the Red Sox. I rooted
for the Yankees, just like my father and his father, whilemy brother, the second born, favored the Sox. This
was the late 1970s, and we compared player to player
(Jackson vs Rice, Guidry vs Tiant), position to posi-
tion, tirelessly trying to convince the other, based on
the past performance of our teams, which was superior,
and each of us leaving the quarrel convinced the other
was a complete idiot.
Fast forward a few decades, transform the 2 brothers
into hematologic malignancy doctors and the school-
yard into a windowless pathology conference room,
and the same passionate dispute shifts to which acute
myeloid leukemia (AML) cytogenetic risk scheme is
the most predictive of survival. The most widely used
are those from the Medical Research Council of the
United Kingdom (now the National Council Research
Institute), each of the 3 U.S. Cooperative Groups, and
the European Organization for Research and Treat-
ment of Cancer/Gruppo Italiano Malattie Ematolo-
giche Dell’ Adulto [1-5]. They overarchingly share
similar characteristics (everyone agrees corebinding fac-
tors are good, complex cytogenetics are bad, and most
